The effects of glycemic index on prostate cancer progression in a xenograft mouse model

被引:0
|
作者
Galvan, Gloria Cecilia [1 ]
Macias, Everardo [2 ]
Sanders, Sergio [1 ]
Ramirez-Torres, Adela [1 ]
Stock, Shannon [3 ,4 ]
You, Sungyong [1 ,5 ]
Riera, Celine E. [6 ,7 ]
Tamukong, Patrick [1 ]
Smith-Warner, Stephanie A. [8 ,9 ]
Genkinger, Jeanine M. [10 ,11 ]
Luthringer, Daniel J. [12 ]
Freeman, Michael R. [1 ]
Freedland, Stephen J. [1 ,4 ]
机构
[1] Cedars Sinai Med Ctr, Dept Urol, Los Angeles, CA 90048 USA
[2] Duke Univ, Sch Med, Dept Pathol, Durham, NC USA
[3] Coll Holy Cross, Dept Math & Comp Sci, Worcester, MA USA
[4] Vet Affairs Hlth Care Syst, Dept Surg, Urol Sect, Durham, NC 27705 USA
[5] Cedars Sinai Med Ctr, Dept Computat Biomed, Los Angeles, CA USA
[6] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA USA
[7] Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA USA
[8] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA
[9] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[10] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA
[11] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA
[12] Cedars Sinai Med Ctr, Dept Pathol, Los Angeles, CA USA
关键词
FACTOR-BINDING PROTEIN-3; GENE-EXPRESSION; CARBOHYDRATE; GROWTH; RISK; LOAD;
D O I
10.1038/s41391-023-00769-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Previously, we found low-carbohydrate diets slowed prostate cancer (PC) growth and increased survival vs. a Western diet in mice, by inhibiting the insulin/IGF-1 axis. Thus, we tested whether modifying carbohydrate quality to lower glycemic index (GI) without changing quantity results in similar benefits as with reduced quantity.Methods: Male SCID mice injected with LAPC-4 cells were single-housed and randomized when their tumors reached 200 mm(3) on average to a LoGI (48% carbohydrate kcal, from Hylon-VII) or HiGI Western diet (48% carbohydrate kcal, from sucrose). Body weight and tumor volume were measured weekly. Body composition was assessed 35 days after randomization. Blood glucose and serum insulin, IGF-1 and IGFBP3 were measured at study end when tumor volumes reached 800 mm(3). We analyzed gene expression of mice tumors by RNA-sequencing and human tumors using the Prostate Cancer Transcriptome Atlas.Results: There were no significant differences in tumor volume (P > 0.05), tumor proliferation (P = 0.29), and overall survival (P = 0.15) between groups. At 35 days after randomization, the LoGI group had 30% lower body fat (P = 0.007) despite similar body weight (P = 0.58). At sacrifice, LoGI mice had smaller livers (P < 0.001) and lower glucose (P = 0.15), insulin (P = 0.11), IGF-1 (P = 0.07) and IGF-1:IGFBP3 ratio (P = 0.05), and higher IGFBP3 (P = 0.09) vs. HiGI, although none of these metabolic differences reached statistical significance. We observed differential gene expression and pathway enrichment in mice tumors by diet. The most upregulated and downregulated gene in the LoGI group showed expression patterns more closely resembling expression in human benign prostate tissue vs. PC.Conclusions: In this single mouse xenograft model, consuming a low GI diet did not delay PC growth or survival vs. a high GI diet despite suggestions of decreased activation of the insulin/IGF-1 pathway. These data suggest that improving carbohydrate quality alone while consuming a high carbohydrate diet may not effectively slow PC growth.
引用
收藏
页码:348 / 354
页数:7
相关论文
共 50 条
  • [1] The effects of glycemic index on prostate cancer progression in a xenograft mouse model
    Gloria Cecilia Galván
    Everardo Macias
    Sergio Sanders
    Adela Ramirez-Torres
    Shannon Stock
    Sungyong You
    Celine E. Riera
    Patrick Tamukong
    Stephanie A. Smith-Warner
    Jeanine M. Genkinger
    Daniel J. Luthringer
    Michael R. Freeman
    Stephen J. Freedland
    Prostate Cancer and Prostatic Diseases, 2024, 27 : 348 - 354
  • [2] Characterization of prostate cancer cell progression in zebrafish xenograft model
    Xu, Wei
    Foster, Britany A.
    Richards, Mackenzie
    Bondioli, Keneth R.
    Shah, Girish
    Gren, Christopher C.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 52 (01) : 252 - 260
  • [3] Antitumor activity of PSMA ADC after progression on docetaxel in a mouse xenograft model of human prostate cancer
    Ma, D.
    Zhang, H.
    Kennedy, B.
    Parsons, T.
    Olson, W. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] ROLE OF METFORMIN IN PROSTATE CANCER PROGRESSION: MECHANISTIC STUDIES IN A XENOGRAFT MODEL
    Hou, Min
    Venier, Natalie
    Sugar, Linda
    Musquera, Mireia
    Pollak, Michael
    Fleshner, Neil
    Klotz, Laurence
    Venkateswaran, Vasundara
    JOURNAL OF UROLOGY, 2010, 183 (04): : E552 - E553
  • [5] Glycemic index, glycemic load and risk of prostate cancer
    Augustin, LSA
    Galeone, C
    Dal Mas, L
    Pelucchi, C
    Ramazzotti, V
    Jenkins, DJA
    Montella, M
    Talamini, R
    Negri, E
    Franceschi, S
    La Vecchia, C
    INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (03) : 446 - 450
  • [6] Rhamnetin inhibits prostate cancer progression in an autochthonous mouse prostate cancer model
    Oak, Christine
    Bhaskaran, Natarajan
    Gupta, Sanjay
    Shukla, Sanjeev
    CANCER RESEARCH, 2015, 75
  • [7] Apalutamide and autophagy inhibition in a xenograft mouse model of human prostate cancer
    Daniel Eberli
    Benedikt Kranzbühler
    Lukas Prause
    Valentin Baumgartner
    Sheryl Preda
    Rosa Sousa
    Fabienne Lehner
    Souzan Salemi
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 3351 - 3360
  • [8] Apalutamide and autophagy inhibition in xenograft mouse model of human prostate cancer
    Salemi, S.
    Kranzbuhler, B.
    Prause, L.
    Baumgartner, V.
    Eberli, D.
    EUROPEAN UROLOGY, 2021, 79 : S607 - S607
  • [9] α-Pinene Inhibits Human Prostate Cancer Growth in a Mouse Xenograft Model
    Zhao, Yunqi
    Chen, Ran
    Wang, Yun
    Yang, Yixin
    CHEMOTHERAPY, 2018, 63 (01) : 1 - 7
  • [10] Apalutamide and autophagy inhibition in a xenograft mouse model of human prostate cancer
    Eberli, Daniel
    Kranzbuhler, Benedikt
    Prause, Lukas
    Baumgartner, Valentin
    Preda, Sheryl
    Sousa, Rosa
    Lehner, Fabienne
    Salemi, Souzan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (12) : 3351 - 3360